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We wished to evaluate the prevalence of cardiovascular (CV) risk factors in patients with
obstructive sleep apnoea syndrome (OSAS) before initiation of continuous positive airway pres-
sure (CPAP), and without any declared or diagnosed pre-existing CV disorder. We wanted to
compare the prevalence of these CV risk factors between men and women in an observational
study. A questionnaire concerning CV risk factors was submitted to the patients, by a respira-
tory home-care technician at the time of installation of the CPAP treatment.
Patients: The study population consisted of 1117 patients; 834 men, 283 women.
Results: The prevalence of arterial hypertension (HT), diabetes, obesity, active smoking,
hyperlipidemia and family history of coronary heart disease was 54.1%, 22.8%, 65.8%, 18.3%,
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1064 J.-P. Laaban et al.Women had significantly more HT (62.1 vs 51.4%), diabetes (29.9 vs 20.4%), obesity (77 vs
62%) and family history of coronary disease (25.1 vs 18.2%). The prevalence of active smoking
was significantly higher in men (20.4 vs 12%). The prevalence of hyperlipidemia was not
different between men and women (34.5 vs 31.8%). Stepwise logistic regression showed that
HT and diabetes were both independently associated with BMI and age, while diabetes and
not HT was independently associated with female gender.
The prevalence of classical CV risk factors was very high in this population with OSAS
requiring CPAP, especially in women. There is thus a very elevated CV risk level independent
of that directly related to OSAS. It is important to screen for and treat classical CV risk factors
in this population.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Cardiovascular (CV) morbidity and mortality are increased in
patients with obstructive sleep apnoea syndrome (OSAS).1,2
Cross-sectional studies have shown that OSAS is an inde-
pendent risk factor for coronary artery disease (CAD) and
stroke.3,4 However the relative risk of CAD associated with
OSAS was weak and did not increase with increasing severity
of OSAS.3
Several observational studies have shown that the inci-
dence of CV complications is increased in untreated OSAS
and decreased with continuous positive airway pressure
(CPAP).5,6 However, in these studies, the control group
consisted of patients refusing CPAP or not complying with it
who were also likely to have poor compliance with CV risk
reduction treatments. Therefore it is not clear how much of
the increased CV risk in apnoeic patients is directly
attributable to the OSAS and how much is related to the
concomitant presence of other classical CV risk factors.
Furthermore studies that have evaluated CV risk factors
in OSAS have certain limitations. In most studies, patients
with pre-existing CV disorders were not excluded, thereby
leading to an overestimation of CV risk factors. The number
of patients included in these studies is very variable.7 The
proportion of patients with severe OSAS is small in many
studies, even in those with large cohorts.3,8 The evaluation
of CV risk factors is often incomplete, especially as regards
the presence of a family history of CAD which is a major risk
factor. Finally, the evaluation of CV risk in OSAS patients
has generally been studied in men only; most studies had
few or no women.5e7,9,10
Thus we set out to study the prevalence of major CV risk
factors in a large population of men and women with OSAS,
requiring CPAP, and free of pre-existing known CV disease.
We wished to compare the prevalence of these risk factors
between men and women.
Patients and methods
Consecutive patients with OSAS were included on CPAP
initiation, over a period of eighteen months, in 10 home-
care associations in the federated ANTADIR network
(Association Nationale pour les Traitements A Domicile, les
Innovations et la Recherche).11 The diagnosis of OSAS was
established by full polysomnography or by nocturnal respi-
ratory polygraphy.This was an observational study. A questionnaire was
given to the patient, at home, by paramedical personnel
from the homecare association, on the day that the CPAP
treatment was initiated. The questionnaire consisted in 38
questions concerning CV risk factors, previous CV events
and medications usually used. If the patient had difficulties
the paramedical helped him to fill out the questionnaire.
The diagnosis of hypertension (HT) and diabetes
depended on the patient replying that he had HT and/or
diabetes or by the identification of treatment for the
condition in the list of medicines taken. Beta-blockers and
ACE-inhibitors were regarded as anti-hypertensive drugs
and not as treatment for heart failure. Angiotensine II-
inhibitors, Ca-channel blockers and diuretics were consid-
ered as anti-hypertensive drugs. Obesity was defined by
a body mass index (BMI) 30 kg/m2, based on weight and
height reported by the patient. Patients were considered as
current smokers in the case of active smoking within the
year. The diagnosis of hyperlipidemia was based on the
patients’ report of the diagnosis and by the identification of
treatment for the condition in the list of medications. The
presence of a family history of CAD was defined by reported
angina, or myocardial infarction or a history of coronary
artery bypass operation, or a history of coronary angio-
plasty before the age of 60 years in any first degree relative
(parent or sibling, or child).
We excluded from analysis patients with pre-existing
coronary artery disease, cerebrovascular disease or
peripheral artery disease. Coronary artery disease was
defined by reported angina, or myocardial infarction or
a history of coronary artery bypass operation, or a history of
coronary angioplasty. Cerebrovascular disease was defined
as reported stroke or surgery or angioplasty of a carotid
artery. Peripheral artery disease was defined by any past
history of surgery or angioplasty of a lower limb artery. We
have therefore excluded 338 patients in whom the ques-
tionnaire revealed a previous cardiovascular disease.
ANTADIR is registered with the National Committee of
Civil Liberties (CNIL). This study was approved by the
Scientific Committee of ANTADIR.
All numerical variables were expressed as mean SD. The
c2 test was used for a comparison of categorical variables
between two groups. For the comparison of numerical
variables between two groups, the Student t test was used. A
p value of< 0.05 was considered as statistically significant.
In the case of finding a difference in the prevalence of a CV
risk factor between men and women, and to determine if this
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a stepwise logistic regression. In this model the CV risk factor
concerned was the dependent variable and gender was one
of the tested independent variables.
Results
The study population consisted of 1117 patients, 834 men
and 283 women, with OSAS requiring CPAP and free of
a known CV disease.
Age, apnoeaehypopnoea index (AHI) and parameters of
nocturnal desaturation did not significantly differ between
men and women (Table 1). The prevalence of severe OSAS
(AHI 30), moderate OSAS (AHI: 15e29.9) and mild OSAS
(AHI: 5e14.9) was respectively 85.6%, 12.2% and 2.2%.
The prevalences of CV risk factors are shown in Table 2.
The prevalences of HT, diabetes, obesity and family history
of CAD were respectively 54.1%, 22.8%, 65.8%, 20% and
were significantly higher in women than in men. The
prevalence of current smoking was 18.3% and was signifi-
cantly higher in men than in women. The prevalence of
hyperlipidemia was 33.8% and did not differ between men
and women.
The percentages of patients with at least two or three of
the following CV risk factors, i.e. hypertension, diabetes or
obesity were significantly higher in women than in men
(Table 3).
In the female population, there were no differences in the
levels of different CV risk factors between those with severe
OSAS, and those with moderate to mild OSAS (Table 4). In the
male population, the prevalence of HTand obesity was higher
in those with severe OSAS than in those with moderate to mild
OSAS (Table 4).
A stepwise logistic regression was carried out to examine
whether the increased prevalence of HT or diabetes was
independently associated with female gender. In the first
model the dependent variable was HT, and the tested
variables were sex, age, BMI, AHI, smoking status and dia-
betes. The variables associated independently with HT
were BMI (p< 0.001), age (p< 0.001) and diabetes
(p< 0.001), but gender was not associated independently
with HT. In the second model, the dependent variable was
diabetes and the tested variables were sex, age, BMI, AHI,
smoking status and HT. The variables associated indepen-
dently with diabetes were BMI (p< 0.001), HT (p< 0.001),
age (p< 0.001), smoking status (pZ 0.003) and femaleTable 1 Age, body mass index (BMI) and nocturnal respiratory d
and women.
All patients (nZ 1117)
Age (years) 57.7 12
BMI (kg/m2) 33.6 7.3
BMI 40 kg/m2 (% pat) 15.8
AHI (/h) 48.6 21.4
Minimal nocturnal SaO2 (%) 70.8 14.6
Mean nocturnal SaO2 (%) 91.3 4
% RT SaO2< 90 % 24.3 25.7
AHI, apnoea-hypopnoea index; RT, recording time.gender (pZ 0.021). Female gender was therefore inde-
pendently and positively associated with diabetes, with and
odds ratio of 1.56 (95% CI:1.07e2.27).
Discussion
This observational study shows that the prevalence of
various CV risk factors was very high in a group of 1117
patents with OSAS, requiring CPAP treatment while not
presenting a known CV illness. The prevalence of HT, dia-
betes, obesity and family history of CAD was greater in
women than in men, while age and the severity of OSAS
were not.
This was an observational study of a large series of
patients in a multicenter home-care system for manage-
ment of patients with CPAP. An auto-questionnaire was
used with assistance given to the patient when required.
Thus there was no specific medical visit for the study. The
patients were interviewed at the time of initiation of CPAP
therapy, at home, and thus there was a large recruitment
over a short period of time.
In our study the prevalence of different CV risk factors,
apart from current smoking was greater than in the general
population: particularly, diabetes, HT and obesity.12e14 The
prevalence of different CV risk factors observed in our
study can be compared with data from the literature as
regards the CV profile of patients with OSAS. In our study,
the prevalence of diabetes was very elevated at 22.8% in
patients with OSAS requiring CPAP. Similar figures have
been noted in the literature6,9 while other studies have
shown a lower prevalence of diabetes in OSAS3,5 which
could be related to the lower age of the patients. In our
study, the prevalence of HT was high (54.1%), and compa-
rable to that usually found in severe OSAS.6,15e19 The
prevalence of obesity was very high in our study (65.8%),
but the prevalence of obesity in OSAS is related to the level
of the AHI.16 The prevalence of hyperlipidemia was
elevated in our study (33.8%) even though the patients did
not have known CV disease. Twenty percent of the patients
in our study had a family history of CAD. This important CV
risk factor20 has not been mentioned in other published
studies evaluating CV risk related to OSAS.5,6,21 Further-
more it has been reported that patients with OSAS had
a greater family history of premature coronary related
death, independently of the presence of CAD associated
with the OSAS.22 The prevalence of current smoking in ourata for the overall population with comparison between men
Men (nZ 834) Women (nZ 283) p
57.7 12 57.7 12.1 NS
32.4 6.2 36.8 9.1 <0.001
10.2 32.5 <0.001
49 20.9 47.2 22.9 NS
71 14.6 70.2 14.8 NS
91.3 4.1 91.3 3.9 NS
23.7 25.2 26 27.1 NS
Table 2 Prevalence of different cardiovascular risk factors for the overall population with comparison between men and
women.
All patients (nZ 1117) Men (nZ 834) Women (nZ 283) p
Hypertension (% pat) 54.1 51.4 62.1 <0.005
Diabetes (% pat) 22.8 20.4 29.9 <0.002
Obesit (BMI 30 kg/m2) (% pat) 65.8 62.0 77.0 <0.001
Current smoker (% pat) 18.3 20.4 12.0 <0.002
Current or ex-smoker (% pat) 66.2 77.0 34.3 <0.001
Hyperlipidemia (% pat) 33.8 34.5 31.8 NS
Family history of CAD (% pat) 20.0 18.2 25.1 <0.005
BMI, body mass index; CAD, coronary artery disease.
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related to OSAS reported comparable or higher or lower
figures.5e7,16,17,19
One important result of the current study is that the
prevalence of most of the CV risk factors was greater in
women than in men. In our study the prevalence of dia-
betes was greater in women than in men. These results are
not in accordance with the data reported in the general
population in whom the prevalence of diabetes is higher in
men than in women.13 This increased prevalence of dia-
betes in women may possibly be explained by the greater
prevalence of obesity in women, in particular massive
obesity. However female gender was in our study an inde-
pendent predictive factor for the prevalence of diabetes.
There are no other data in the literature concerning the
prevalence of diabetes in women with severe OSAS, since
most studies did not include women5,9 or did not compare
the prevalence of diabetes between men and women with
OSAS.6 We have no explanation accounting for our finding of
an independent association between female gender and
diabetes which should be confirmed by further studies.
The prevalence of HT was higher in women than in men
in our study. This is surprising since male gender is a well
known risk factor for HT. This increased prevalence of HT in
women was not explained by greater age, nor by more
severe OSAS, but most probably by a greater prevalence of
obesity, and in particular massive obesity in women in our
study.
The prevalence of obesity was greater in women than in
men in this study, and massive obesity was three times
more frequent in women. It has been shown that the level
of obesity necessary to cause OSAS is higher in women than
in men, aged under 65 years.21 The prevalence of hyper-
lipidemia was not different between men and women inTable 3 Number of cardiovascular (CV) risk factors per patient
with comparison between men and women.
All patient
No of CV risk factors per patient 2.1 1.3
3 CV risk factors (3e6) per patient (% pat) 39.8
At least hypertension and obesity (% pat) 41.5
At least diabetes and obesity (% pat) 18.8
At least hypertension and diabetes (% pat) 16.7
At least hypertension, diabetes and obesity (% pat) 14.4this study, whilst in the general population, hyperlipidemia
is more frequent in men.12,13 In this study women had
a greater level of family history of coronary disease without
any evident explanation. We have noted a greater level of
smoking in men than in women, as is common in the
general population,12 and confirmed in patients with
OSAS.21
In this study the prevalence of CV risk factors was not
significantly influenced by the severity of OSAS in women,
whilst in men the prevalence of HT and obesity was much
higher in severe OSAS than in mild-moderate OSAS. These
data suggest that the proportion of cardiovascular risk
directly attributable to OSAS is greater in men than in
women.
The prevalence of CV risk factors, although high, may be
underestimated in this study. We only took into account
patients with previously known diabetes, and a certain
number of apnoeic patients may have had occult dia-
betes.23 Studies using ambulatory control of blood pressure
over 24 h showed that HT is often underdiagnosed by
standard clinical methods in patients with OSAS.24 We only
took into account patients with hyperlipidemia treated by
lipid lowering agents. In studies with systematic measure-
ment of blood lipid levels the prevalence of hyperlipidemia
was higher.6,7
The high levels of CV risk factors in this study could be
explained by the fact that OSAS may favour the develop-
ment of certain CV risk factors, especially HT. Transverse
and longitudinal studies have shown that OSAS is an inde-
pendent risk factor for HT,8,15e17,25 but the relative risk of
HT independently related to OSAS is not very high.26,27
We have found an elevated level of CV risk factors in this
population with OSAS. However, this can be considered as
a selected population, given that recruited patients haveand association of CV risk factors for the overall population
s (nZ 1117) Men (nZ 834) Women (nZ 283) p
2.1 1.3 2.4 1.3 <0.001
37.3 47 <0.005
38.4 50.9 <0.01
16.1 26.9 <0.001
14.5 23 <0.001
12.1 21.2 <0.001
Table 4 Comparison of the prevalence of different cardiovascular risk factors between patients with mild-moderate
OSAS(AHIZ 5e29.9) and patients with severe OSAS(AHI 30) for the overall population with comparison between men and women.
All patients AHIZ 5e29.9 (nZ 161) AHI 30 (nZ 956) p
Hypertension (% pat) 45.0 55.7 <0.001
Diabetes (% pat) 16.9 23.8 NS
Obesity (BMI 30 kg/m2) (% pat) 50.3 68.4 <0.001
Current smoker (% pat) 18.0 18.3 NS
Hyperlipidemia (% pat) 32.3 34.1 NS
Family history of CAD (% pat) 20.5 19.9 NS
Age (years) 56.6 12.2 57.9 12.0 NS
Women AHIZ 5e29.9 (nZ 52) AH 30 (nZ 231) p
Hypertension (% pat) 60.8 62.4 NS
Diabetes (% pat) 23.5 31.3 NS
Obesity (BMI30 kg/m2) (% pat) 69.2 78.8 NS
Current smoker (% pat) 13.5 11.7 NS
Hyperlipidemia (% pat) 25.0 33.3 NS
Family history of CAD (% pat) 23.1 25.5 NS
Age (years) 58.0 11.7 57.7 12.2 NS
Men AHIZ 5e29.9 (nZ 109) AHI 30 (nZ 725) p
Hypertension (% pat) 37.6 53.5 <0.001
Diabetes (% pat) 13.8 21.4 NS
Obesity (BMI 30 kg/m2) (% pat) 41.3 65.1 <0.001
Current smoker (% pat) 20.2 20.4 NS
Hyperlipidemia (% pat) 35.8 34.3 NS
Family history of CAD (% pat) 19.3 18.1 NS
Age (years) 56.0 12.3 58.0 11.9 NS
BMI, body mass index; CAD, coronary artery disease.
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and subsequently recommended for treatment. Thus the
level of CV risk in a population with suspected OSAS may
well be different and likewise in a population with OSAS but
not recommended for treatment. Indeed patients with
OSAS but with no other concomitant health problems are
probably less likely to visit a doctor and may thus be
underrepresented in our population. Likewise, women tend
to seek medical help more than men, but there may be
a counteracting bias against diagnosing OSAS in women.
Indeed men without concomitant disease may be induced
to visit a doctor at the behest of their partner more than
the inverse situation.
CPAP treatment is reimbursed in France when the
patient has over 30 respiratory events per hour or over 10
respiratory related micro-arousals per hour, with symp-
toms. Thus in this series the patients could be considered to
be more severely affected than in North American. Thus
a high proportion of patients can be classed as having
severe sleep apnoea, but in contrast we have excluded
patients with known CV disease.
It could be argued that there is a bias to treat OSAS
patients with CV risk factors with CPAP, but no figures exist
as to the proportion of known OSAS patients untreated nor
as to the relative proportions of patients having other
treatment options such as surgery or mandibular advance-
ment prosthesis.
Thus this selected population that is physician referred
and with severe OSAS, has a high incidence of CV riskfactors. Our findings sustain the idea that such patients
merit screening for CV risk factors and health advice aimed
to reduce such risks. In order to diminish CV morbidity and
mortality it is essential to optimally treat CV risk factors
and this is probably as important as treating effectively the
sleep apnoea.
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